Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VAX-PG
- Development stage
- Discontinued
- Lead developer
- Vaxcyte
- Modality
- Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
01
Overview
VAX-PG is a novel therapeutic vaccine candidate developed by Vaxcyte targeting the keystone pathogen responsible for periodontitis, a highly prevalent oral disease. The vaccine leverages a cell-free protein synthesis platform to produce high-fidelity protein antigens that closely mimic those of native pathogens, enabling the development of “tough-to-make” antigens. Its primary goal is to slow or stop the progression of periodontal disease by stimulating an immune response against key bacterial drivers of periodontitis. As of June 2025, it remains in preclinical development[1][2][3].
- Brand names
- VAX-PG
- Other names
- VAX-PG
Beyond the preview
Go deeper on VAX-PG.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VAX-PG.